

Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Feb-2025  
 Document Type: USP Monographs  
 DocId: GUID-C3EA9EE6-2613-467C-941C-F08E4809F499\_8\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M3807\\_08\\_01](https://doi.org/10.31003/USPNF_M3807_08_01)  
 DOI Ref: 9q9h3

© 2025 USPC  
 Do not distribute

## Nicardipine Hydrochloride Injection

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click  
<https://www.uspnf.com/rb-nicardipine-hcl-inj-20250131>.

### DEFINITION

Nicardipine Hydrochloride Injection is a sterile solution of Nicardipine Hydrochloride. It contains NLT 90.0% and NMT 110.0% of the labeled amount of nicardipine hydrochloride ( $C_{26}H_{29}N_3O_6 \cdot HCl$ ).

### IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Buffer:** 1.36 g/L of [monobasic potassium phosphate](#) in [water](#)

**Mobile phase:** [Methanol](#) and [Buffer](#) (80:20)

**Diluent:** [Acetonitrile](#) and [Buffer](#) (50:50)

**Standard solution:** 0.1 mg/mL of [USP Nicardipine Hydrochloride RS](#) in [Diluent](#). Sonication may be used to aid in dissolution. Pass through a suitable filter of 0.45- $\mu$ m pore size. Discard the first 2–3 mL of the filtrate.

**Sample solution:** Nominally 0.1 mg/mL of nicardipine hydrochloride in [Diluent](#) from a suitable volume of [Injection](#). Pass through a suitable filter of 0.45- $\mu$ m pore size. Discard the first 2–3 mL of filtrate. [NOTE—The *Sample solution* is stable for about 26 h.]

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

**Column:** 4.6-mm  $\times$  25-cm; 5- $\mu$ m packing [L1](#)

**Column temperature:** 40°

**Flow rate:** 1 mL/min

**Injection volume:** 20  $\mu$ L

**Run time:** NLT 2 times the retention time of nicardipine

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of nicardipine hydrochloride ( $C_{26}H_{29}N_3O_6 \cdot HCl$ ) in the portion of [Injection](#) taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of nicardipine from the *Sample solution*

$r_S$  = peak response of nicardipine from the *Standard solution*

$C_S$  = concentration of [USP Nicardipine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of nicardipine hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

## IMPURITIES

### • LIMIT OF *N*-BENZYL-*N*-METHYL-ETHANOLAMINE

**Solution A:** Dissolve 2.80 g of sodium perchlorate monohydrate in 1 L of water. Adjust with perchloric acid to a pH of 2.5.

**Solution B:** Acetonitrile and methanol (50:50)

**Diluent:** Acetonitrile and water (20:80)

**Mobile phase:** See Table 1.

**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	95	5
10	82	18
12	20	80
22	20	80
24	95	5
32	95	5

**Standard solution:** 2.5 µg/mL of USP *N*-Benzyl-*N*-methyl-ethanolamine RS in *Diluent* prepared as follows. To a suitable amount of USP *N*-Benzyl-*N*-methyl-ethanolamine RS, add *Diluent* to 70% of the final volume. Sonicate to dissolve. Cool, and dilute with *Diluent* to volume. Pass the solution through a suitable filter of 0.45-µm pore size.

**Sample solution:** Nominally 0.5 mg/mL of nicardipine hydrochloride in *Diluent* from a suitable volume of *Injection*. Pass the solution through a suitable filter of 0.45-µm pore size.

## Chromatographic system

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 205 nm

**Column:** 4.6-mm × 15-cm; 5-µm packing L1

### Temperatures

**Autosampler:** 10°

**Column:** 30°

**Flow rate:** 1.5 mL/min

**Injection volume:** 50 µL

## System suitability

**Sample:** *Standard solution*

### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 5.0%

## Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of *N*-benzyl-*N*-methyl-ethanolamine in the portion of *Injection* taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of *N*-benzyl-*N*-methyl-ethanolamine from the *Sample solution*

$r_S$  = peak response of *N*-benzyl-*N*-methyl-ethanolamine from the *Standard solution*

$C_s$  = concentration of [USP N-Benzyl-N-methyl-ethanolamine RS](#) in the *Standard solution* (mg/mL)

$C_u$  = nominal concentration of nicardipine hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** NMT 0.7%

• **ORGANIC IMPURITIES**

**Solution A:** 3.5 g/L of [sodium perchlorate monohydrate](#) in [water](#). Add 1 mL/L of [triethylamine](#), and adjust with [perchloric acid](#) to a pH of 2.0.

**Solution B:** [Acetonitrile](#) and [methanol](#) (70:30)

**Mobile phase:** See [Table 2](#).

**Table 2**

Time (min)	Solution A (%)	Solution B (%)
0	70	30
15	70	30
55	35	65
60	35	65
62	70	30
70	70	30

**Standard solution:** 0.02 mg/mL of [USP Nicardipine Hydrochloride RS](#) in [methanol](#) prepared as follows. To a suitable amount of [USP Nicardipine Hydrochloride RS](#) add [methanol](#) to 60% of the final volume. Sonicate to dissolve. Cool, and dilute with [methanol](#) to volume.

Pass the solution through a suitable filter of 0.45-μm pore size.

**Sensitivity solution:** 0.002 mg/mL of [USP Nicardipine Hydrochloride RS](#) in [methanol](#) from *Standard solution*

**Sample solution:** Nominally 2 mg/mL of nicardipine hydrochloride in [methanol](#) from a suitable volume of *Injection*. Pass the solution through a suitable filter of 0.45-μm pore size. [NOTE—The *Sample solution* is stable for about 42 h at 10°.]

**Chromatographic system**

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 239 nm

**Column:** 4.6-mm × 15-cm; 5-μm packing [L1](#)

**Temperatures**

**Autosampler:** 10°

**Column:** 50°

**Flow rate:** 1 mL/min

**Injection volume:** 10 μL

**System suitability**

**Samples:** *Standard solution* and *Sensitivity solution*

**Suitability requirements**

**Tailing factor:** NMT 2.0, *Standard solution*

**Relative standard deviation:** NMT 5.0%, *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each specified impurity and any unspecified degradation product in the portion of *Injection* taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (1/F) \times 100$$

$r_u$  = peak response of each specified impurity or any unspecified degradation product from the *Sample solution*

$r_s$  = peak response of nicardipine from the *Standard solution*

$C_S$  = concentration of [USP Nicardipine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of nicardipine hydrochloride in the *Sample solution* (mg/mL)

$F$  = relative response factor (see [Table 3](#))

**Acceptance criteria:** See [Table 3](#).

**Table 3**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Nicardipine monoacid (nicardipine related compound A) <sup>a</sup>	0.72	1.00	0.2
Nicardipine pyridine analog (nicardipine related compound B) <sup>b</sup>	0.94	0.42	2.5
Nicardipine	1.00	1.00	—
Any unspecified degradation product	—	—	0.2
Total impurities <sup>c</sup>	—	—	3.5

<sup>a</sup> 5-(Methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.

<sup>b</sup> 3-{2[Benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate.

<sup>c</sup> Total impurities include the sum of all organic impurities and N-benzyl-N-methyl-ethanolamine.

## OTHER COMPONENTS

### • CONTENT OF SORBITOL (if present)

**Buffer:** 1 g/L of [tetrabutylammonium hydrogen sulfate](#) in [water](#)

**Mobile phase:** [Acetonitrile](#) and **Buffer** (70:30)

**Standard solution:** 4.8 mg/mL of [USP Sorbitol RS](#) in *Mobile phase*. Pass the solution through a suitable filter of 0.45- $\mu$ m pore size. Sonication may be necessary to aid in dissolution.

**Sample solution:** Nominally 4.8 mg/mL of sorbitol in *Mobile phase* from the contents of NLT 3 Injection vials. Pass the solution through a suitable filter of 0.45- $\mu$ m pore size. [NOTE—*Sample solution* is stable for about 24 h.]

## Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** Refractive index

**Column:** 4.6-mm  $\times$  25-cm; 5- $\mu$ m packing [L8](#)

### Temperatures

**Column:** 40°

**Detector:** 50°

**Flow rate:** 1 mL/min

**Injection volume:** 25  $\mu$ L

**Run time:** NLT 2 times the retention time of sorbitol

## System suitability

**Sample:** *Standard solution*

### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of the labeled amount of sorbitol ( $C_6H_{14}O_6$ ) in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 $r_U$  = peak response of sorbitol from the Sample solution $r_S$  = peak response of sorbitol from the Standard solution $C_S$  = concentration of [USP Sorbitol RS](#) in the Standard solution (mg/mL) $C_U$  = nominal concentration of sorbitol in the Sample solution (mg/mL)**Acceptance criteria:** 90.0%–110.0%**SPECIFIC TESTS**

- [BACTERIAL ENDOTOXINS TEST \(85\)](#): Meets the requirements
- [STERILITY TESTS \(71\)](#): Meets the requirements
- [pH \(791\)](#): 3.0–4.2
- [PARTICULATE MATTER IN INJECTIONS \(788\)](#): Meets the requirements for small-volume injections
- **OTHER REQUIREMENTS:** Meets the requirements for [Injections and Implanted Drug Products \(1\)](#).

**ADDITIONAL REQUIREMENTS****Change to read:**

- **PACKAGING AND STORAGE:** Preserve in single-dose glass vials. ▲Protect from light.▲ (RB 1-Feb-2025) Store at controlled room temperature.
- **LABELING:** Label it to indicate that it is to be diluted to the appropriate strength with a suitable intravenous fluid prior to administration.

- [USP REFERENCE STANDARDS \(11\)](#):

[USP N-Benzyl-N-methyl-ethanolamine RS](#)2-[Benzyl(methyl)amino]ethanol.  
 $C_{10}H_{15}NO$  165.23[USP Nicardipine Hydrochloride RS](#)[USP Sorbitol RS](#)D-Glucitol.  
 $C_6H_{14}O_6$  182.17**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NICARDIPINE HYDROCHLORIDE INJECTION	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 44(4)

**Current DocID: GUID-C3EA9EE6-2613-467C-941C-F08E4809F499\_8\_en-US****DOI:** [https://doi.org/10.31003/USPNF\\_M3807\\_08\\_01](https://doi.org/10.31003/USPNF_M3807_08_01)**DOI ref:** [9q9h3](#)